Section 5 of 6
Economic information and modeling report
12 evidence topics · 1 source
Modeling overview
Summary
An abstract-only preprint describes an illustrative Spanish managed-access model for saroglitazar. Its prices and spending estimates are modeled, not observed commercial prices or payer expenditure. The full model was unavailable for appraisal.
Budget impact model
Approach and framework
Perspective and time frame
Epidemiology and eligible population inputs
UDCA-response population
National population estimate and modeled cohort size
No evidence found.
Cost assumptions
Risk-adjusted annual price
Model outcomes
Willingness-to-pay thresholds
| Parameter | Quoted value |
|---|---|
| Lower threshold, euros per QALY | “€25,000” |
| Higher threshold, euros per QALY | “€30,000” |
| Expected net monetary benefit across modeled subgroups | “negative” |
Results
Base case
Modeled 24-month costs
| Outcome | Quoted value |
|---|---|
| Net health-system cost | “€4,371,005” |
| Savings versus financing without risk sharing | “€586,495” |
Scenario analyses
Stress scenario
| Parameter or outcome | Quoted value |
|---|---|
| Monte Carlo simulation | “10,000 iterations” |
| Stress percentile | “95th-percentile” |
| Late-progression cases | “19” |
| Incremental drug-side budget risk absorbed | “75%” |
Budget impact model discussion
Summary
Savings compare risk sharing with financing the same drug without risk sharing, not with usual care. Expected net monetary benefit remained negative at both tested thresholds. These results do not establish conventional cost-effectiveness.